The clinical-stage biotech highlighted in today’s article, dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders, has been one of the hottest biotech stocks this year. And after a run-up that has generated triple-digit returns, there are a number of factors that could help propel it to even higher highs from here. For more on this stock, CLICK HERE.
